Ligand Pharmaceuticals
LGND
346 hedge funds and large institutions have $5.3B invested in Ligand Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 124 increasing their positions, 130 reducing their positions, and 19 closing their positions.
116% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 19
42% more call options, than puts
Call options by funds: $27.5M | Put options by funds: $19.4M
30% more capital invested
Capital invested by funds: $4.09B → $5.3B (+$1.21B)
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
6.94% more ownership
Funds ownership: 187.67% → 194.61% (+6.9%)
6% more funds holding
Funds holding: 326 → 346 (+20)
5% less repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 130
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$58.5M |
| 2 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$45.5M |
| 3 |
BlackRock
New York
|
+$44.9M |
| 4 |
Renaissance Technologies
New York
|
+$28.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$38.1M |
| 2 |
DMK
David M. Knott
|
-$37.4M |
| 3 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
-$25M |
| 4 |
IAM
Impax Asset Management
Portsmouth,
New Hampshire
|
-$14M |
| 5 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
-$13.9M |
LGND Hedge Fund Activity: Q2 2018 in Review
346 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2018, worth a combined $5.3B — up 30% from $4.09B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new LGND positions and 19 closed out — a net gain of 22 holders — while 124 added to existing stakes and 130 trimmed.
The largest buyer was Manulife (Manufacturers Life Insurance), adding an estimated $58.5M. The largest seller was Bank of America, cutting an estimated $38.1M.
- 346 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2018, up from 326 in Q1 2018.
- Funds reported $5.3B of Ligand Pharmaceuticals stock for Q2 2018, up 30% quarter-over-quarter.
- 41 funds opened new Ligand Pharmaceuticals positions in Q2 2018 and 19 closed out, a net change of +22 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2018 was Manulife (Manufacturers Life Insurance), an estimated $58.5M added.
- The largest Ligand Pharmaceuticals seller in Q2 2018 was Bank of America, an estimated $38.1M sold.
Based on aggregated 13F filings for Q2 2018.